INspire technology, a novel and proprietary technology, developed by Biond for the internalization of antibodies into cells, addressing “undruggable” intracellular targets and leading to breakthrough therapies.
Practically all biologic therapeutic agents (Biologics), mainly monoclonal antibodies, are directed against extracellular or plasma soluble targets. However, the inner side of cells holds a vast variety of therapeutically relevant and potent targets. Biologics cannot enter living cells. Currently used small-molecule based drugs are either not specific or selective enough or cannot address targets based on protein-protein interactions.
To address intracellular targets, Biond is developing a platform technology based on the conjugation of a payload antibody to a chemically modified protein carrier. The carrier’s modification enables its efficient internalization with the payload to the cytoplasm, following successful escape from the endosomal pathway.
Following successful functional in vitro PoCs, Biond is currently evaluating the in vivo profile of its INspire Biologics and commencing the development of its first intracellular drug candidate for HPV-positive cancers.
A model describing Biond’s carrier and payload intracellular delivery technology: A protein carrier is chemically modified and further conjugated to a payload antibody against an intracellular target (left). The chemical modification enables the carrier-payload conjugate to cross the cell membrane and escape the endosomal pathway. Once in the cytoplasm the payload is detached from the carrier to roam around and locate and bind its target (right)